Bicalutamide API supplied as a pharmaceutical-grade powder for tablet, capsule, granule, and injectable development is the racemic nonsteroidal antiandrogen N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide, CAS 90357-06-5, molecular formula C₁₈H₁₄F₄N₂O₄S, and molecular weight 430.37 g/mol. The API is produced under ICH Q7 pharmaceutical GMP and released against the current USP and Ph.Eur. monographs where the substance is listed. The product is supplied in unmicronized, jet-milled micronized, and injectable-audited low-bioburden physical grades. These grade designations describe process provenance, environmental control, and final analytical testing, not a change in chemical identity. For oral solid dosage development, the low aqueous solubility of bicalutamide makes dissolution rate sensitive to particle-size distribution, polymorphic form, and agglomeration history. For injectable development, the same active compound is nominated only where dedicated low-bioburden or sterile-audited batches are selected, because compendial parenteral requirements for bacterial endotoxins, sterility, and subvisible particles impose additional controls that are not automatically met by oral-grade material.

As a solid, bicalutamide is practically insoluble in water and soluble in several organic solvents including methanol, acetone, and dimethylformamide. The aqueous solubility is pH-dependent but remains low across the physiological pH range. No universal particle-size specification is assigned by the USP or Ph.Eur. monograph; the micronized grade is therefore controlled to a customer-specific D90 value with a typical upper range of 15 µm to 20 µm for oral solid dosage development. The unmicronized grade is used where subsequent dry milling or granulation is preferred. The injectable-audited grade is controlled for low bioburden, but it is not necessarily sterile; terminal sterilization or aseptic processing of the finished injectable formulation is required.

What compendial controls apply when a single API is designated for both oral and injectable use?

In oral solid dosage forms, the release specification is built around the USP or Ph.Eur. monograph for bicalutamide, supplemented by ICH Q3C residual solvents and ICH Q3D elemental impurities. The table below lists the core release parameters and the corresponding test designations. For injectable-grade material, USP <71> sterility and USP <85> bacterial endotoxins are added. The endotoxin limit is not a fixed product constant; it is derived from the maximum recommended adult dose per kilogram of body weight and the intended route of administration. A parenteral product requiring a low endotoxin limit cannot be qualified from oral-grade material simply by retesting sterility, because upstream bioburden and packaging controls differ.

The micronized grade is typically milled in a fluid energy mill using nitrogen or dried compressed air. Laser diffraction data are reported as D10, D50, and D90 under USP <429>. Because no universal pharmacopeial particle-size limit exists for bicalutamide, the D90 target is set by the formulation development team and the regulatory filing. The injectable-audited grade may be further processed by sieving or terminal treatment; if terminal treatment is used, chemical stability and polymorphic integrity must be confirmed by HPLC and XRPD after treatment.

On production tablet lines, the behavior of bicalutamide is governed less by its chemical identity than by the particle size and flow properties of the selected grade. Unmicronized bicalutamide exhibits cohesive, poorly flowing behavior in many direct-compression trials; therefore, tableting campaigns frequently employ dry granulation, roller compaction, or slugging to densify and size the API-containing blend before compression. A representative process sequence includes blending bicalutamide with lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, followed by roller compaction to produce ribbons with a target solid fraction. Tablet breaking force is monitored under USP <1217>, and friability is tested according to USP <1216>. Dissolution acceptance for immediate-release bicalutamide tablets is set through USP <711>; because of the low aqueous solubility, the dissolution medium commonly contains a surfactant concentration that is justified by solubility data rather than plain aqueous buffer. For capsules, the risk profile shifts from tableting mechanics to powder flow into the dosing disc and potential segregation. Micronized API can improve dissolution rate but can reduce bulk density and flow consistency. Semiautomatic capsule filling machines with auger or dosator systems require blend density and fill weight control; fill weight uniformity is evaluated under USP <905>. Batch-to-batch variability in particle-size distribution at D90 below 10 µm has been observed to change capsule dissolution profiles even when blend potency remains compliant; therefore, particle-size release data should be trended as part of process verification rather than treated as a one-time powder characterization. For both tablets and capsules, the main difference from a freely soluble API is that formulation success is tied to dissolution-rate control through particle engineering and deagglomeration.

Granule processing and the dissolution-rate dependency on particle size

Wet granulation of bicalutamide-containing formulations is specified where direct compression cannot accommodate a high drug load or where densification is required to reduce dust and segregation. High-shear granulation with water or an aqueous binder solution is generally possible, but the low solubility of the API does not remove the need for wet massing time control; overwetting can produce hard, poorly disintegrating granules, while underwetting can yield weak granules with a high fines fraction. In fluid-bed drying, inlet air temperature is typically maintained in the range of 50°C to 60°C for bicalutamide granulations, with final moisture content set below 3.0% by loss on drying. The exact endpoint is established by granule size distribution, compressibility, and subsequent tablet hardness. For dry granulation, roller compaction parameters such as roll pressure, roll gap, and screen mill speed are adjusted to achieve a granule fraction between 20 mesh and 80 mesh; the specific range depends on the formulation. Bicalutamide brittleness and particle-size reduction during compaction should be evaluated, because excessive fines can reverse the flow improvement gained by granulation. Granule particle size is measured by sieve analysis under USP <786>, and tapped density is measured under USP <616> to track blend densification. In all cases, the dissolution method in USP <711> remains the primary release control linking physical processing to product performance. If micronized API is used, deagglomeration in the granulation step must be confirmed; agglomerated micronized powder can produce a dissolution profile equivalent to an unmicronized grade, undermining the process objective.

For injectable formulations, the critical quality attributes of the API shift from flowability and compressibility to bioburden, endotoxin, and the absence of particulate contamination. Bicalutamide is practically insoluble in water; therefore, aqueous injectable formulations are not simple solutions unless a cosolvent, cyclodextrin, or surfactant system is used, or unless the product is a suspension. Where a suspension is developed, particle size and particle-size stability during autoclaving or aseptic processing require specific attention. An injectable-grade bicalutamide API lot should be manufactured in segregated equipment with controlled bioburden before dry filling or terminal treatment. If dry heat or gamma irradiation is used to reduce bioburden, chemical stability and polymorphic integrity must be verified by the same HPLC and X-ray powder diffraction methods used for release. Published data for specific radiation doses on bicalutamide powder are limited; therefore, a sterilization validation program must generate the data before the injectable grade is released. Testing of the finished injectable product for sterility is performed under USP <71>, bacterial endotoxins under USP <85>, and particulate matter under USP <788> for large-volume parenterals or USP <789> for small-volume parenterals. The packaging of injectable-grade API is typically double polyamide pouches inside an outer aluminum foil liner, with a desiccant where moisture sensitivity has been demonstrated. Subvisible particle testing on the API alone is not an adequate release test for a suspension product; the particle-size distribution and particle morphology must be controlled after homogenization and terminal processing.

When bicalutamide is compared with flutamide, nilutamide, and enzalutamide, the processing distinctions arise from solubility, molecular weight, and compendial status

Among nonsteroidal antiandrogens, bicalutamide is widely used in tablet and capsule development because its once-daily oral dosing and long elimination half-life permit low dose strengths, but from a manufacturing perspective the relevant comparison is physical. Bicalutamide has a molecular weight of 430.37 g/mol, higher than flutamide (276.21 g/mol) and nilutamide (317.22 g/mol) and lower than enzalutamide (464.44 g/mol). The compound is BCS Class II, meaning that dissolution-rate management through particle engineering is a primary formulation control. Flutamide and nilutamide are earlier-generation compounds with shorter half-lives and their own compendial specifications; bicalutamide differs by a sulfonyl linkage and a cyano-trifluoromethyl aromatic substituent, which contribute to its low aqueous solubility and high protein binding. Compared with enzalutamide, bicalutamide has a smaller molecular volume and different solid-state behavior, but both compounds require dissolution-rate management in oral solid dosage forms. In terms of regulatory status, bicalutamide is described in the USP and Ph.Eur. monographs; for any comparator the exact monograph status should be confirmed against the current edition because adoption varies. The difference between bicalutamide and first-generation alternatives is not confined to receptor affinity or half-life; for the formulator, the practical differences are particle-size sensitivity, low solubility, and the need to justify dissolution media for release testing.

Where the material is supplied for regulatory submission, the following control domains are relevant:

Because bicalutamide is an antiandrogen, manufacturing suites are typically operated with local exhaust ventilation and powder containment appropriate for the pharmacological activity. An occupational exposure limit or containment band should be derived from the pharmacological activity and occupational toxicology review rather than from a universal regulatory value. Cross-contact with other potent APIs is prevented through dedicated or campaign-based cleaning validation under 21 CFR 211.67. The choice of oral-grade or injectable-grade bicalutamide API is therefore a release, packaging, and process-history decision, not merely a chemical identity statement.